跳至主要内容
临床试验/NCT02200809
NCT02200809已完成不适用

MR-guided Focal Laser Ablation of the Prostate

Radboud University Medical Center4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2014年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
4
主要终点
Disease free survival

研究概览

简要总结

Purpose of the investigators study is to determine the short and medium term histological cancer control of focal therapy using MR-guided focal laser ablation therapy in the treatment of localised prostate cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Newly diagnosed and biopsy proven prostate cancer
  • Intermediate risk patients (PSA <= 20 ng/mL, Gleason ≤ 7, T2b)
  • No previous treatment for prostate cancer
  • Cancer lesion located at least 1 cm away from the neurovascular bundle according to Multimodality MR images
  • Signed informed consent by patient
  • Age 18 years or older
  • Signed screening form (to determine exclusion for metal device/foreign bodies/claustrophobia)

排除标准

  • Impossibility to obtain a valid informed consent
  • Patients unable to undergo MR imaging, including those with contra-indications
  • Contra-indications to MR guided focal laser therapy (colitis ulcerosa, rectal pathology or abdomino perineal resection)
  • Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging
  • Patients with evidence for nodal or metastatic disease
  • Patients with an estimated Glomerular Filtration Ratio (eGFR) < 40 mL/min/1.73 m2

结局指标

主要结局

Disease free survival

时间窗: 36 months.

The short and medium term histological cancer control defined as the percentage of patients with disease free survival according to the pathological MR-guided biopsy results after 36 months.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验